Cardinal Health is moving lower even after reporting fiscal third-quarter 2026 results that beat expectations on adjusted earnings and included a higher, narrower full-year outlook. The selling appears tied to headline quality: GAAP profitability and below-the-surface metrics (including cash-flow) are drawing attention and encouraging profit-taking after a strong run, even as management raised FY2026 non-GAAP diluted EPS guidance to $10.70–$10.80. (newsroom.cardinalhealth.com)

For the quarter, Cardinal Health reported revenue of $60.9 billion, up 11% year over year, while adjusted EPS came in at $3.17 and topped consensus expectations cited in market reports. Management lifted FY2026 adjusted earnings guidance to $10.70–$10.80, pointing to momentum in the core pharmaceutical distribution engine and demand for specialty and branded drugs. (newsroom.cardinalhealth.com)

Even with a guidance increase, investors appear to be discounting the print due to the gap between strong non-GAAP performance and less favorable GAAP/cash-flow signals highlighted in post-earnings coverage, including commentary that GAAP earnings were pressured by items such as impairment charges and that free cash flow metrics were weaker versus the prior year period. In other words, the stock is being treated as a “quality of earnings” story today, not just an “EPS beat” story. (tipranks.com)

Key swing factors from here include whether pharmaceutical and specialty growth can stay strong enough to sustain the higher FY2026 outlook, and whether cash generation improves as the fiscal year progresses. Investors will also listen for updates on segment profitability trends and any repeatable drivers behind the raised guidance versus one-time items that could fade. (newsroom.cardinalhealth.com)